1. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration;Knudsen;J Med Chem,2000
2. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects;Vilsbøll;J Clin Endocrinol Metab,2003
3. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men;Agersø;Diabetologia,2002
4. The molecular basis for the delayed absorption of the once-daily human GLP-1 analogue, liraglutide;Steensgaard;Diabetes,2008
5. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers;Nauck;J Clin Endocrinol Metab,2002